Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANTXR1 (TEM8) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANTXR1 ECD-Fc Fusion Protein / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Ideal for internalization and binding studies. |
View ANTXR1 Products |
| Gene Delivery | ANTXR1 Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell line construction, ideal for internalization, internalization assays, and live-cell imaging. |
View ANTXR1 Products |
| Benchmark Ab | Anti-ANTXR1 Recombinant Reference Antibody Positive control for assay validation with defined CDR sequences. |
View ANTXR1 Products |
| Validator | ANTXR1 siRNA Set (3 unique sequences) Knockdown verification and specificity controls. |
View ANTXR1 Products |
| Related Target: ANTXR2 (CMG2) | Essential counter-screening target; shares ~55% homology with ANTXR1. Off-target liability assessment critical for safety. | View ANTXR2 Products |
| Related Target: VEGFR2 (KDR) | Synergistic target in tumor angiogenesis and microenvironment; useful for combination therapy studies. | View VEGFR2 Products |
| Related Target: ITGB1 (Integrin β1) | Functional interaction partner of ANTXR1 for adhesion and TME remodeling mechanisms. | View ITGB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity screening against ANTXR2 (CMG2) | Homolog panel proteins (ANTXR1 & ANTXR2) highly purified and strictly sequence verified by mass spectrometry. Defined extracellular domain boundaries. |
| Cross-species (Mouse/Cyno) evaluation for IND-enabling tox | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence-verified ECD domains, preserving native glycosylation. |
| ADC Internalization efficiency testing | ECD-Fc fusion optimized for fluorophore conjugation; Lentivirus available for live-cell imaging and pH-sensitive internalization assays. HEK293 expressed proteins preserve native conformation. |
| Lack of clinical controls / assay standardization | Reference-grade antibodies with defined CDR sequences; recombinant positive controls included. |
| False positives / off-target binding | Validated siRNA included for specificity checks; ANTXR2 negative control protein available. |
Live ANTXR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ANTXR1 (Tumor Endothelial Marker 8) therapeutics is intensifying, representing a specialized yet high-value niche in solid tumor oncology. As a Type I transmembrane protein selectively overexpressed on tumor endothelial cells, stromal cells, and certain sarcoma subtypes (while largely absent in normal adult tissues), ANTXR1 offers a unique opportunity for anti-angiogenic therapy and outside-in tumor attack. Current development is heavily weighted toward Antibody-Drug Conjugates (ADCs) targeting the extracellular domain, with increasing attention on epitope selection to minimize vascular toxicity while maximizing tumor penetration. Major players are shifting from traditional mAbs to next-generation modalities: ADCs with novel payloads, CAR-T for solid tumors, bispecifics, and targeted radioligands. The next wave of R&D is focusing on epitope-engineered internalizing antibodies with improved therapeutic windows, particularly for soft tissue sarcoma, triple-negative breast cancer, and other angiogenic solid tumors. First-generation therapies are entering the clinic, and the pipeline landscape is expected to expand into combination regimens with anti-PD-1/L1 or anti-angiogenic agents to address the aggressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Emerging Biotechs, Oncology-Focused Pharma | Soft Tissue Sarcoma, Metastatic Solid Tumors, Gastrointestinal Cancers | Internalization Assay (Need high-purity ECD-Fc with native glycosylation) |
| CAR-T / NK Cell Therapy | Academic Centers (e.g., UPenn), Cell Therapy Biotechs | Triple-Negative Breast Cancer, Sarcoma, Solid Tumors | Selectivity Assay (Need high-purity ANTXR1 vs ANTXR2 proteins) |
| Bispecific Antibodies | Immunotherapy Innovators | Refractory Angiogenic Cancers | Cross-reactivity Panel (Need ANTXR1/ANTXR2 ortholog discrimination) |
| mAb / Anthrax Toxin Derivative | Various Biotechs | Broad Solid Tumors | In vivo modeling (Need cross-reactive Mouse/Cyno proteins) |
| Targeted Radioligand | Precision Oncology Developers | Tumor Imaging, Radiotherapy | Binding Affinity Validation (Need stable cell lines via Lentivirus) |